PTPN11 and acute myeloid leukemia: A comprehensive analysis considering resistance-conferring mutations (e.g., PTPN11) or the detection of individual phospho-proteome signatures able to reveal aberrant activation of signaling pathways able to mediate venetoclax resistance (e.g., MAPK activation) can contribute to improve future AML therapy.